|Day Low/High||81.05 / 84.81|
|52 Wk Low/High||79.13 / 106.74|
There still will be winners and losers, but the new administration's FDA is a net plus for the industry.
Big gains could be ahead for investors willing to stick with the stock, according to one firm.
My three top predictions for the next six months.
From Abbott Labs to Wynn, these names rate checking out.
It's a wonder to me how split this market really is.
It's been a heavy week for earnings, but Jim Cramer is already looking ahead to next week -- and Apple.
Brineura is first and only treatment for CLN2 disease, a form of Batten disease.
Home builders make up the second-largest allocation in my portfolio, behind biotech.
The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 793,152 share increase in total short interest for BioMarin Pharmaceutical Inc. , to 8,456,120, an increase of 10.35% since 12/15/2016.
There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
Actelion was too pricey. Now J&J is looking for another acquisition.
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
Here are Monday's top research calls, including upgrades for Biogen and Time Warner, and downgrades for GoPro and L Brands.
The most recent short interest data has been released for the 10/14/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.